Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by the degeneration of substantia nigra dopaminergic neurons. Many therapeutic strategies were explored for PD with no success. In this study, we investigated the efficacy of graphene oxide nanoparticles (GONPs) using the reserpine model of PD. Low concentrations GONPs were utilized as a therapeutic agent in many neurodegenerative diseases. We assessed the neurobehavioral alterations in the reserpine model of PD and investigated the neuroprotective and antioxidant effects of GONPs in this model. Thirty male mice were separated into three groups (N=10): C (control); Res (Reserpine 0.25mg/kg); Res+GONPs (Reserpine 0.25mg/kg and GONPs 25mg/kg). Our results showed that reserpine neurotoxicity induced hypoactivity with a significant increase of superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA) levels in the brain and brainstem. GONPs reversed the reserpine-induced hypoactivity concomitant with decreased neuronal CAT and MDA levels. These findings support the potential use of GONPs as an antioxidant agent in the central nervous system (CNS) that protects against neurodegeneration in the reserpine PD model.